Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.

Blood - 1 Feb 2008

Saddler Chris, Ouillette Peter, Kujawski Lisa, Shangary Sanjeev, Talpaz Moshe, Kaminski Mark, Erba Harry, Shedden Kerby, Wang Shaomeng, Malek Sami N

Abstract excerpt

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies. Patients with relapsed or resistant CLL have a significantly shortened lifespan. MDM2 inhibitors have been developed and may have significant potential in the treatment of CLL. Clinical development of these compounds would be aided through knowledge of molecular predictors of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosome Aberrations
Share to Chromosomes, Human, Pair 17

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Dosage

Share to In Situ Hybridization, Fluorescence

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Loss of Heterozygosity

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 17971485
DOI: 10.1182/blood-2007-09-112698

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.PMID 17971485Read ↗

The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis.Semantic proximity Read ↗

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatmentSemantic proximity Read ↗

Molecular biomarkers in chronic lymphocytic leukemia.Semantic proximity Read ↗

The clinical implications of gene mutations in chronic lymphocytic leukaemia.Semantic proximity Read ↗

The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implicationsSemantic proximity Read ↗

RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.Semantic proximity Read ↗

Drug-perturbation-based stratification of blood cancerSemantic proximity Read ↗

Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.Semantic proximity Read ↗

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.